Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Harsanyi Zsolt	2. Issuer Name and Ticker or Trading Symbol Aptevo Therapeutics Inc. [ APVO ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050	3. Date of Earliest Transaction (MM/DD/YYYY) 7/27/2020
(Street) SEATTLE, WA 98121 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$41.16 ⁽¹⁾	7/27/2020		D			1339 ⁽¹⁾	⁽²⁾	8/3/2026	Common Stock	1339 ⁽¹⁾	⁽³⁾	0	D
Stock Option (right to buy)	$30.10 ⁽¹⁾	7/27/2020		D			892 ⁽¹⁾	⁽⁴⁾	6/1/2027	Common Stock	892 ⁽¹⁾	⁽³⁾	0	D
Stock Option (right to buy)	$76.86 ⁽¹⁾	7/27/2020		D			1785 ⁽¹⁾	⁽⁵⁾	6/1/2028	Common Stock	1785 ⁽¹⁾	⁽³⁾	0	D
Stock Option (right to buy)	$8.56	7/27/2020		A		1322		⁽⁶⁾	7/26/2030	Common Stock	1322	⁽³⁾	1322	D
Stock Option (right to buy)	$8.56	7/27/2020		A		170		⁽⁷⁾	7/26/2030	Common Stock	170	⁽³⁾	170	D

Explanation of Responses:
(1)	Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020.
(2)	These options vested in three approximately equal annual installments beginning on August 3, 2017.
(3)	In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4.
(4)	These options vested in three approximately equal annual installments beginning on June 1, 2018.
(5)	These options provide for vesting in three approximately equal annual installments beginning on May 31, 2019. Prior to July 27, 2020, all but 595 shares of the issuer's common stock underlying this stock option had vested.
(6)	These options vest in full on the one year anniversary of the date of grant.
(7)	These options will vest in three approximately equal annual installments beginning on the one year anniversary of the date of grant.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Harsanyi Zsolt C/O APTEVO THERAPEUTICS INC. 2401 4TH AVENUE, SUITE 1050 SEATTLE, WA 98121	X